Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of “Hold” by Analysts

Novavax, Inc. (NASDAQ:NVAXGet Rating) has received an average recommendation of “Hold” from the nine brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $77.43.

A number of equities research analysts have commented on the company. Jefferies Financial Group assumed coverage on Novavax in a research report on Friday, December 2nd. They set a “hold” rating for the company. Cowen cut their price target on Novavax to $55.00 in a research note on Thursday, October 13th. B. Riley cut their price target on Novavax from $74.00 to $37.00 and set a “buy” rating for the company in a research note on Monday, January 9th. StockNews.com raised Novavax from a “sell” rating to a “hold” rating in a research note on Saturday, November 19th. Finally, HC Wainwright cut their price target on Novavax from $207.00 to $110.00 and set a “buy” rating for the company in a research note on Friday, December 30th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC bought a new position in Novavax in the 2nd quarter worth approximately $47,000. Geneos Wealth Management Inc. increased its position in Novavax by 124.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,809 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 1,004 shares during the period. Forsta AP Fonden bought a new position in Novavax in the 2nd quarter worth approximately $103,000. Neo Ivy Capital Management bought a new position in Novavax in the 3rd quarter worth approximately $37,000. Finally, US Bancorp DE grew its holdings in shares of Novavax by 41.8% during the 1st quarter. US Bancorp DE now owns 2,083 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 614 shares in the last quarter. 45.70% of the stock is owned by institutional investors.

Novavax Stock Down 3.1 %

NASDAQ:NVAX opened at $11.55 on Wednesday. Novavax has a 1-year low of $8.75 and a 1-year high of $101.39. The firm has a market capitalization of $906.72 million, a price-to-earnings ratio of -0.67 and a beta of 1.89. The stock has a fifty day simple moving average of $13.75 and a 200 day simple moving average of $26.81.

Novavax (NASDAQ:NVAXGet Rating) last released its quarterly earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($2.15) earnings per share for the quarter, missing analysts’ consensus estimates of $2.21 by ($4.36). The company had revenue of $734.58 million during the quarter, compared to analyst estimates of $555.50 million. During the same period last year, the business earned ($4.31) EPS. The firm’s revenue for the quarter was up 310.7% compared to the same quarter last year. Equities analysts predict that Novavax will post -7.49 earnings per share for the current year.

About Novavax

(Get Rating)

Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Read More

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.